Weekly Emails to Hospital C-Suite Halt Two Decades of Superbug Outbreak

Washington, DC, April 29, 2014 /3BL Media/ – Efforts to reduce and stop the spread of infections caused by a highly resistant organism, carbapenem-resistant Acinetobacter baumannii, at a large Florida hospital proved ineffective until they added another weapon – weekly emails from the medical director of Infection Control to hospital leadership, according to a study published in the May issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

When the hospital added the step of sending comprehensive weekly reports to physician, hospital nursing, medical, and administrative leadership, the rate of A. baumannii transmission decreased by 63 percent, according to the research team from the University of Miami Miller School of Medicine. Prior to this, endemic rates of A. baumannii had been present at the institution for nearly two decades.

“These regular highly visible communications allowed us to create a sense of accountability for new cases that unified both the leadership and providers toward the common goal of decreasing new acquisitions of carbapenem-resistant A. baumannii,” state the study authors.

The study analyzed a 42-month period of hospital data (January 1, 2010 to June 30, 2013) representing 1.1 million patient days. During Phase 1 (2010-2011), the bundle of interventions had been implemented but rates had not changed. During Phase 2 (2011-2012), the medical director of Infection Control sent weekly emails to hospital leadership describing and interpreting the surveillance results from the previous week, including the number and location of newly discovered isolates; results of environmental cultures obtained from bed rails, bedside tables, intravenous pumps, and nursing stations; and a map indicating the location of carbapenem-resistant A. baumannii positive patients and objects. Two intensive care units (ICUs) with the highest rates received daily emails. During Phase 3 (2012-2013), the bundle of interventions continued but the weekly emails ceased because there were only scattered weekly acquisitions. Overall acquisition of new cases of carbapenem-resistant A. baumannii decreased from 5.13 per 10,000 patient days in Period 1, to 1.93 in Period 3.

“These weekly emails not only packaged information on the number and locations of new acquisitions of A. baumannii, but also described and explained the results of environmental initiatives, hand culture results, and identification of shared objects among patients,” add the authors. “Additionally, these communications advised the hospital and each ICU’s leaders about the infection control data and provided action plans based on the findings.”

The bundle of infection prevention measures included 1) patient screening tests upon admission to the ICU and weekly thereafter; 2) isolation and separation of patients testing positive for A. baumannii; 3) weekly sampling of surfaces in the hospital environment to assess thoroughness of cleaning; 4) hand hygiene interventions, including random cultures of healthcare workers’ hands, the results of which were included in the weekly reports; 5) observing shared objects that moved from patient-to-patient; and 6) monthly multidisciplinary meetings to discuss all issues related to implementing the bundle.

The authors conclude, “This is the first study to examine the effect of mass electronic dissemination of results from a bundle of interventions. Weekly electronic communications were associated with a striking decrease in the rate of new acquisitions of A. baumannii at our institution probably because of a combination of education, communication, feedback, and peer pressure.”

Acinetobacter baumannii is a type of gram-negative bacteria that is resistant to most antibiotics and has become one of the most worrisome and frequent organisms causing healthcare-associated infections in U.S. healthcare facilities.

Infections from A. baumannii occur mainly in intensive care units and affect primarily very ill, wounded, or immunocompromised patients. The germ can remain on wet or dry surfaces for longer than most other organisms, making it harder to eradicate. Multidrug-resistant Acinetobacter is classified as a serious threat by the Centers for Disease Control and Prevention.

About AJIC: American Journal of Infection Control
AJIC: American Journal of Infection Control covers key topics and issues in infection control and epidemiology. Infection preventionists, including physicians, nurses, and epidemiologists, rely on AJIC for peer-reviewed articles covering clinical topics as well as original research. As the official publication of APIC, AJIC is the foremost resource on infection control, epidemiology, infectious diseases, quality management, occupational health, and disease prevention. AJIC also publishes infection control guidelines from APIC and the CDC. Published by Elsevier, AJIC is included in MEDLINE and CINAHL.

About APIC
APIC’s mission is to create a safer world through prevention of infection. The association’s more than 15,000 members direct infection prevention programs that save lives and improve the bottom line for hospitals and other healthcare facilities. APIC advances its mission through patient safety, implementation science, competencies and certification, advocacy, and data standardization. Visit APIC online at www.apic.org. Follow APIC on Twitter: http://twitter.com/apic and Facebook: www.facebook.com/APICInfectionPreventionandYou. For information on what patients and families can do, visit APIC’s Infection Prevention and You website at www.apic.org/infectionpreventionandyou. 

Notes for editors
“Control of a two-decade endemic situation with carbapenem-resistant Acinetobacter baumannii: electronic dissemination of a bundle of interventions,” by L. Silvia Munoz-Price, Philip Carling, Timothy Cleary, Yovanit Fajardo-Aquino, Dennise DePascale, Adriana Jimenez, Michael Hughes, Nicholas Namias, Louis Pizano, Daniel H. Kett, and Kristopher Arheart, appears in the American Journal of Infection Control, Volume 42, Issue 5 (May 2014).

Authors:
L. Silvia Munoz-Price, MD, PhD (Corresponding Author)
Dept of Medicine, University of Miami Miller School of Medicine, Miami, FL

Philip Carling, MD
Boston University, Boston, MA

Timothy Cleary, PhD
Dept of Pathology, University of Miami Miller School of Medicine, Miami, FL

Yovanit Fajardo-Aquino, MD
Jackson Memorial Hospital, Miami, FL

Dennise DePascale, MT
Jackson Memorial Hospital, Miami, FL

Adriana Jimenez, MT
Jackson Memorial Hospital, Miami, FL

Michael Hughes
Jackson Memorial Hospital, Miami, FL

Nicholas Namias, MD
Dept of Surgery, University of Miami Miller School of Medicine, Miami, FL

Louis Pizano, MD
Dept of Surgery, University of Miami Miller School of Medicine, Miami, FL

Daniel H. Kett, MD
Dept of Medicine, University of Miami Miller School of Medicine, Miami, FL

Kristopher Arheart, EdD
Dept of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL

---

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Liz Garman
+1 202 454 2604
egarman@apic.org